Castle Biosciences, Inc.
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify th…
Medical - Diagnostics & Research
US, Friendswood [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Castle Biosciences, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2019 | - | -0.978 | - | 45 | - | -26 | - | -10 | - | -12 | - | 37 |
| 2020 | 0.3500 | -0.406 | 51 | 61 | 5 | -10 | 7 | -14 | 7 | -16 | 29 | 50 |
| 2021 | -0.5400 | -1.459 | 62 | 92 | -10 | -30 | -7 | -38 | -6 | -42 | 48 | 92 |
| 2022 | -1.2400 | -2.722 | 94 | 135 | -31 | -45 | -36 | -45 | -40 | -86 | 86 | 112 |
| 2023 | -2.5800 | -2.605 | 137 | 209 | -67 | -57 | -58 | -50 | -91 | -95 | 143 | 155 |
| 2024 | -2.1400 | 0.352 | 219 | 325 | -57 | 9 | -45 | -64 | -67 | -76 | 180 | 269 |
| 2025 | - | -1.975 | - | 267 | - | -57 | - | -52 | - | -62 | - | 220 |
| 2026 | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F7X/td> | - | 2.F71/td> | - | 2.F71 | - | 2.F71 |
| 2027 | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F8X/td> | - | 1.F81/td> | - | 1.F81 | - | 1.F81 |
| 2028 | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F9X/td> | - | 0.F91/td> | - | 0.F91 | - | 0.F91 |